GlassScriptPhysician profile
Michael J Pendola
NPI 1932279577
$20,969.49
in general payments reported to CMS, 2019-2025
36 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $644 · 2021: $1,112 · 2022: $10K · 2023: $6,859 · 2024: $847 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $2,178.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,132.29 | 2022-2024 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $2,228.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $954.97 | 2019-2025 | Entyvio, Gattex |
| Thd America, INC. | $443.68 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $390.18 | 2019-2024 | Dificid |
| Stryker Corporation | $213.62 | 2019-2022 | |
| Organon LLC | $159.95 | 2021-2025 | Renflexis, Hadlima |
| Tetraphase Pharmaceuticals, INC. | $113.92 | 2019 | |
| Medical Device Business Services, INC. | $112.12 | 2019 | |
| Ethicon US, LLC | $109.19 | 2021-2025 | Echelon; Endopath |
| Medtronic, INC. | $107.33 | 2021-2025 | Ligasure, Signia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.75 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $79.96 | 2019 | |
| Tela Bio, INC. | $75.38 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Axonics, INC. | $73.20 | 2020-2023 | Axonics |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $66.70 | 2019-2022 | |
| Braintree Laboratories, INC. | $66.60 | 2021-2022 | |
| Acell, INC. | $66.06 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $62.69 | 2024-2025 | Vowst |
| Integra Lifesciences Corporation | $55.45 | 2020-2022 | |
| Allergan, INC. | $51.35 | 2020 | |
| Mallinckrodt Hospital Products INC. | $45.65 | 2020 | |
| Innovation Technologies INC | $39.43 | 2021-2023 | Irrisept |
| Medtronic USA, INC. | $38.75 | 2020 | |
| Amgen INC. | $23.18 | 2022 | |
| Avanos Medical | $22.10 | 2022 | |
| Janssen Biotech, INC. | $21.30 | 2025 | Tremfya |
| Cumberland Pharmaceuticals, INC. | $21.17 | 2022 | |
| Celltrion USA INC. | $20.98 | 2025 | Vegzelma |
| Davol INC. | $17.12 | 2019 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Acacia Pharma INC | $15.01 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.72 | 2023 | |
| Covidien LP | $12.86 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.62 | 2021 | |
| Qol Medical, LLC | $4.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pendola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.